Fülöp, B.; Fischer, J.; Hahn, M.; Böhlig, A.; Matz-Soja, M.; Berg, T.; van Bömmel, F.
Prospective Analysis of Safety and Efficacy of Tenofovir Alafenamide Fumarate (TAF) in European Real-World Patients with Chronic Hepatitis B: A Single-Centre Real-Word Cohort Study. Pathogens 2024, 13, 820.
https://doi.org/10.3390/pathogens13090820
AMA Style
Fülöp B, Fischer J, Hahn M, Böhlig A, Matz-Soja M, Berg T, van Bömmel F.
Prospective Analysis of Safety and Efficacy of Tenofovir Alafenamide Fumarate (TAF) in European Real-World Patients with Chronic Hepatitis B: A Single-Centre Real-Word Cohort Study. Pathogens. 2024; 13(9):820.
https://doi.org/10.3390/pathogens13090820
Chicago/Turabian Style
Fülöp, Balazs, Janett Fischer, Magdalena Hahn, Albrecht Böhlig, Madlen Matz-Soja, Thomas Berg, and Florian van Bömmel.
2024. "Prospective Analysis of Safety and Efficacy of Tenofovir Alafenamide Fumarate (TAF) in European Real-World Patients with Chronic Hepatitis B: A Single-Centre Real-Word Cohort Study" Pathogens 13, no. 9: 820.
https://doi.org/10.3390/pathogens13090820
APA Style
Fülöp, B., Fischer, J., Hahn, M., Böhlig, A., Matz-Soja, M., Berg, T., & van Bömmel, F.
(2024). Prospective Analysis of Safety and Efficacy of Tenofovir Alafenamide Fumarate (TAF) in European Real-World Patients with Chronic Hepatitis B: A Single-Centre Real-Word Cohort Study. Pathogens, 13(9), 820.
https://doi.org/10.3390/pathogens13090820